Showing 4501-4510 of 23267 results for "".
Addressing Equity Gaps in Psoriasis Research
https://reachmd.com/series/c-suite-chats/addressing-equity-gaps-in-psoriasis-research/33151/LaShell Robinson, Head, Global Feasibility and Trial Equity for Takeda, discusses the disproportionate underrepresentation of certain racial and ethnic groups in clinical trials, especially for psoriasis, and how Takeda is seeking to close those gaps in recent Phase 3 trials.Octane Aesthetics Tech Forum: Longevity Medicine Specialist Dr. Elizabeth Yurth Excited Field Is Entering Aesthetics
https://reachmd.com/programs/modern-aesthetics/octane-aesthetics-tech-forum-longevity-medicine-specialist-dr-elizabeth-yurth-excited-field-is-entering-aesthetics/32737/Elizabeth Yurth, MD, ABARM, FAARM, FSSP, is co-founder and chief medical officer of Boulder Longevity Institute in Colorado. Dr. Yurth has a profound background specializing in orthopedic medicine prior to adventuring into the longevity, regenerative, and anti-aging medicine specialty. Dr. Yurth telPediatric, Acne, and AD Sessions: Dr. Eichenfield
https://reachmd.com/conferences/maui-derm-hawaii-2025/pediatric-acne-and-ad-sessions-dr-eichenfield/32684/Lawrence Eichenfield, MD, discusses his presentations from Maui Derm 2025, which included "Pediatric Dermatology 2025," "Update 2025: Acne and Rosacea," and "Atopic Dermatitis and Pruritus: Current Concepts and Therapeutics for 2025." Highlights include the importance of recognizing severe and rapidNKX019: A Potential New Frontier in Generalized Myasthenia Gravis Therapy
https://reachmd.com/programs/neurofrontiers/nkx019-a-potential-new-frontier-in-generalized-myasthenia-gravis-therapy/30066/Read about NKX019, a new CAR cell therapy that will soon enter clinical trials as a potential treatment for generalized myasthenia gravis.Beyond Transplant: Advancements in Primary Biliary Cholangitis Treatment
https://reachmd.com/programs/gi-insights/beyond-transplant-advancements-in-primary-biliary-cholangitis-treatment/29158/Here’s how second-line treatments have impacted the overall management approach to primary biliary cholangitis.Genetic Guidance in Action: A Study for Selecting Oral P2Y Inhibitor
https://reachmd.com/programs/heart-matters/genetic-guidance-in-action-a-study-for-selecting-oral-p2y-inhibitor/15464/What were the results and conclusions of this study among CYP2C19 LOF carriers with CAD? Check it out here.Trends Shaping Aesthetics in America
https://reachmd.com/ma-issues-index/2022-nov-dec/trends-shaping-aesthetics-in-america/35229/The trends plastic surgeons and dermatologists are seeing in practice.#NephMadness & A Look at Sessions on Transplant at NKF
https://reachmd.com/programs/nkf-action-center/nephmadness-a-look-at-sessions-on-transplant-at-nkf/13625/What do we need to know about #NephMadness?ASN 2021: Kidney Care Amid the COVID-19 Pandemic: Strategies for Supply & Staffing Shortages
https://reachmd.com/programs/asn-action-center/kidney-care-amid-the-covid-19-pandemic-strategies-for-supply-staffing-shortages/13139/COVID-19 has impacted care across all specialties. Here’s how one nephrologist adapted her practice.ASN 2021: Emerging Research from Days 1 & 2 of the Annual Meeting
https://reachmd.com/programs/asn-action-center/emerging-research-from-days-1-2-of-the-asn-annual-meeting/13046/Here's a breakdown of some of the emerging research from the first and second day of the 2021 American Society of Nephrology Annual Meeting.